ASND — Ascendis Pharma A/S Share News
0.000.00%
Last trade - 00:00- $15.00bn
- $14.59bn
- €720.13m
BioMarin climbs on global patent settlement with Ascendis
Brief: Ascendis Announces Oral Presentation Of Week 104 Data From Its Pivotal Trial Of Transcon® CNP (Navepegritide) At Isds 2026
Brief: Eyconis Announces Initiation Of First-In-Human Clinical Trial Of Eyc-0305 In Treatment-Naïve Wet Age-Related Macular Degeneration Patients
Ascendis Pharma A/S reports results for the quarter ended June 30 - Earnings Summary
Ascendis Pharma swings to Q2 profit on revenue doubling, PRV sale
Ascendis Pharma A/S expected to post earnings of €1.38 a share - Earnings Preview
Ascendis Pharma A/S expected to post earnings of €1.38 a share - Earnings Preview
Brief: Ascendis Pharma A/S - Announces Week 104 Data From Approach Trial Of Transcon CNP In Children With Achondroplasia
Brief: 5-Year Phase 2 Data Show Transcon® Pth Replicated Systemic Actions Of Endogenous Pth In Adults With Hypoparathyroidism
Denmark's Ascendis Pharma Q1 revenue more than doubles on YORVIPATH sales
NASDAQ RESUMED AT 06:20 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:26 PM
Ascendis Pharma A/S reports results for the quarter ended June 30 - Earnings Summary
Ascendis Pharma A/S expected to post a loss of €1.25 a share - Earnings Preview
Ascendis Pharma A/S reports results for the quarter ended March 31 - Earnings Summary
Ascendis Pharma A/S expected to post a loss of €1.47 a share - Earnings Preview
Ascendis Pharma A/S reports results for the quarter ended December 31 - Earnings Summary
Ascendis Pharma A/S expected to post a loss of €1.08 a share - Earnings Preview
Ascendis Pharma A/S expected to post a loss of €1.14 a share - Earnings Preview